Agonist Potency

Agonist potency is the concentration or dose of an agonist required to produce a specified biological response, making it a key measure of drug activity in pharmacology. It is commonly quantified from a concentration-response curve using the EC50, the concentration that produces 50% of the maximal response, while receptor affinity, receptor coupling, and cellular signaling can influence the measured value. Potency differs from efficacy, which describes the maximum response an agonist can produce, so a highly potent drug is not necessarily the most effective. Comparing potency across compounds helps researchers characterize receptor pharmacology, interpret dose-response experiments, guide lead optimization, and anticipate concentration ranges for further preclinical or clinical evaluation.

Agonist Potency - Related Videos

Research

JoVE Journal - Biochemistry

Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays

0 Views •

Cited by 1 •

2016

Peptide adsorption to plasticware during traditional tip-based serial dilutions can significantly impact potency determination and confound the understanding of structure-activity relationships used for lead identification and lead optimization phases of drug discovery. Here methods for automated acoustic non-contact serial dilution of peptide samples are described.

Quantifying Agonist Activity at G Protein-coupled Receptors

0 Views •

Cited by 10 •

2011

A method for estimating the affinity constant of an agonist for the active state (Kb) of a G protein-coupled receptor is described. The analysis provides absolute or relative measures of Kb depending on whether constitutive receptor activation is measurable. Our method applies to various responses downstream from receptor activation.

Education

JoVE Core - Pharmacology

Glucagon-like Receptor Agonists

0 Views •

2024

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP. GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Adrenergic Agonists: Therapeutic Uses

0 Views •

2023

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies. Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension. Allergies and anaphylaxis:...

Stimulation of Dorsal Root Ganglion Sensory Neurons Using a Neuropeptide Receptor Agonist

0 Views •

2025

This video demonstrates the use of transfected dorsal root ganglion cells to study neurotransmitter release by stimulating them with a neuropeptide receptor agonist.

View All Results

FAQs

Related Topics